Eyal Rubin

Eyal Rubin is the EVP and Chief Financial Officer at Brainstorm Cell Therapeutics. Prior to this, they served as the Academic Affairs and Networks Project Leader at Teva Pharmaceuticals from September 2020 to June 2022. In this role, they were responsible for identifying and managing a portfolio of strategic scientific collaborations with academic partners to enhance Teva's future drug discovery and novel therapeutics development.

From August 2019 to September 2020, Rubin served as Senior Scientist and Study Director at Crown Bioscience, Inc. In this role, they oversaw scientific research studies and managed a team of scientists.

From May 2018 to June 2022, Rubin served as Scientific Advisor at ImmunoHiTech LTD. In this role, they provided scientific advice and guidance to the company.

From November 2011 to May 2014, Rubin served as Senior Scientist at LifeMap Sciences. In this role, they conducted scientific research and experiments.

From September 2011 to May 2012, Rubin taught the Science Excellence Program at Kinneret Academic College. In this role, they educated students on the principles of science and encouraged them to pursue careers in science and technology.

Eyal Rubin studied medical science at The Hebrew University of Jerusalem before completing a Master's degree in Clinical Biochemistry at Tel Aviv University. Eyal then went on to earn a Doctor of Philosophy in Imnuno-Oncology and Personalized Medicine from Bar-Ilan University.

They work with Alex Burshtein - Quality Assurance Manager, Revital Aricha - VP Research & Development, and Ralph Kern - Chief Operating Officer and Chief Medical Officer. Their manager is Chaim Lebovits, President & CEO.